Health and Healthcare

Celgene, Gilead, Biogen and More Major Biopharmas Reporting This Week

Chris Lange

Published: October 22, 2017 10:45 am

Last Updated: January 12, 2020 6:57 am

Third-quarter earnings reporting season is now well under way. So far, things are looking good. The health care sector has yet to see any significant earnings representation, but that will change during the week of October 23 to October 27. At least eight large biopharma outfits are scheduled to report their latest earnings and revenues.

24/7 Wall St. has included the consensus earnings estimates from Thomson Reuters, as well as the stock price and trading history.

Be advised that the earnings and revenue estimates may change ahead of the formal reports, and some companies change earnings dates as well.

Also check out our separate previews of some top Dow companies and other prominent companies on deck to share their latest results this week.

Biogen Inc. (NASDAQ: BIIB) is expected to report its third-quarter results early on Tuesday. The consensus forecast calls for $5.70 in earnings per share (EPS) and revenue of $3.03 billion. Shares of Biogen ended last week at $338.10. The consensus analyst price target is only $336.79. The 52-week trading range is $244.28 to $348.84.

Eli Lilly and Co. (NYSE: LLY) is set to report its third-quarter results Tuesday morning as well. The analysts’ consensus estimates are $1.03 in EPS on revenue of $5.52 billion. Shares were changing hands at $87.23 on Friday’s close. The consensus price target is $91.05, and the 52-week range is $64.18 to $89.09.

Amgen Inc. (NASDAQ: AMGN) will share its most recent quarterly results late Wednesday. The consensus estimates are $3.11 in EPS and $5.75 billion in revenue. Shares closed at $182.96 on Friday, in a 52-week range of $133.64 to $191.10. The stock has a consensus price target of $190.50.

Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) is scheduled to reveal its third-quarter results Thursday morning. The consensus forecast calls for EPS of $1.32 and $864.45 million in revenue. Shares were trading at $139.02 on Friday’s close. The consensus price target is $163.25, while the 52-week range is $96.18 to $149.34.

Bristol-Myers Squibb Co. (NYSE: BMY) also is expected to post its third-quarter results Thursday morning. The consensus forecast calls for EPS of $0.77 and $5.19 billion in revenue. Shares ended last week at $64.42 apiece. The consensus price target is $60.68, while the 52-week range is $46.01 to $66.10.

24/7 Wall St.
10 Speculative Analyst Stocks With Huge Potential Upside

Celgene Corp. (NASDAQ: CELG) is set to report its third-quarter results Thursday morning as well. The analysts’ consensus estimates are $1.87 in EPS on revenue of $3.41 billion. Shares were changing hands at $121.33 on Friday’s close. The consensus price target is $154.38, and the 52-week range is $96.93 to $147.17.

Gilead Sciences Inc. (NASDAQ: GILD) third-quarter results are due late on Thursday. The consensus forecast calls for $2.11 in EPS and revenue of $6.36 billion. The shares ended last week at $81.21. The consensus analyst target is $84.95. The 52-week trading range is $63.76 to $86.27.

And AbbVie Inc. (NYSE: ABBV) will share its most recent quarterly results early Friday. The consensus estimates are $1.38 in EPS and $7.0 billion in revenue. Shares closed at $96.10 on Friday, in a 52-week range of $55.06 to $98.26. The stock has a consensus price target of $92.67.